SCIL has a pipeline of five proprietary products from SCC to be made in India in the next two years and evaluating and discussing more.

Chirag Batavia • 30 August 2021

Sumitomo Chemicals India Ltd (SCIL)

  • SCIL is part of Japan-based Sumitomo Chemical Company (SCC) and has a robust product portfolio which is diversified across agrochem value chain and also diversified across key crops.

  • We believe that SCIL is well placed against its domestic peers in terms of advantage of strong parentage, robust product pipeline, wide distribution and opportunities from contract manufacturing in future.

  • SCIL has a pipeline of five proprietary products from SCC to be made in India in the next two years and evaluating and discussing more.

  • We believe that SCC group’s acquisition of Nufram’s Latin American agrochem distribution business is expected to result in strong exports opportunity for SCIL.

  • SCIL has reported strong Q1FY22 performance. We expect 14.9% and 23% CAGR in revenue and PAT, respectively in FY21-24E with RoCE and RoEs of over 25% and 20%, respectively.

  • We value the stock at ~40x September 2023E earnings, based on merits against its domestic and MNC peers in the sector.

Note: The above is a brief note on the company, based on the inputs of KIE research report dated 6 th August 2021, which is available on their website at: https://www.kotaksecurities.com/ksweb/ResearchCall/Fundamental . Disclaimer: http://bit.ly/2n5AxIE

Looking to invest in Sumitomo Chemicals India and other Indian stocks? Open your demat & trading account with Lakshit Financial

Lakshit Financial Authorized Person of Kotak Securities Limited in cash segments of BSE & NSE and NSE F&O segments with NSE. Lakshit Financial registration number: BSE CASH AP0106730124228 | NSE CASH AP029177621 | NSE F&O AP029177621.Registered Office: Lakshit Financial, ASM 7, Ashwin Sector, Mumbai Agra Highway, CIDCO, Nasik 422009, Maharashtra, India. Kotak Securities Limited. Registered Office: 27 BKC, C 27, G Block, Bandra Kurla Complex, Bandra (E), Mumbai 400051. CIN: U99999MH1994PLC134051. SEBI Registration No. INZ000200137 (Member of NSE, BSE, MSE, MCX & NCDEX). Member Id: NSE-08081; BSE-673; MSE-1024; MCX-56285; NCDEX-1262. AMFI ARN 0164, PMS INP000000258 and Research Analyst INH000000586. NSDL/CDSL: IN-DP-NSDL-23-97.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please refer the Risk Disclosure Document issued by SEBI and go through the Rights and Obligations and Do's and Dont's issued by Stock Exchanges and Depositories before trading on the Stock Exchanges .

DID YOU KNOW, as an NRI , you can invest in IPOs and purchase shares, ETFs or convertible debentures of an Indian company through stock exchanges. All it takes is linking your NRO or NRE account to an active Demat account in India on a repatriable or non-repatriable basis, based on your requirements. Click here to learn more about NRI Demat & Trading Account.

OPEN YOUR ACCOUNT NOW !

Fill in your details and we will get in touch with you.

Products and services available only for People of Indian Origin

Note:  Please note that by submitting the above mentioned details, you are authorising Lakshit Financial to call you and send promotional communication even though you may be registered under DNC. Also, all calls with Lakshit Financial representatives may be recorded for internal quality & training purposes

Looking to invest in HOME FIRST FINANCE (HOMEFIRST) and other Indian stocks? Open your NRI Demat Acc
30 December 2024
Home First Finance (HOMEFIRST) Home First remains consistent on operational and financial parameters. Home First (HFFC) reported 24% earnings growth, with 19% net interest income growth in Q2FY25. Gross stage-3 ratio was flat qoq at 1.7%, stage-2 ratio declined 6 bps qoq to 1.1%. While other asset classes have reported mixed trends residential home loans, as an asset class, continues to stand tall. Home First, with 85% home loan exposure, is well-placed on the above. We expect the company to deliver 25% earnings CAGR for FY25-27E. We remain assertive with a BUY rating and FV of Rs1,360 (no change). Note: The above is a brief note on the company, based on the inputs of KIEresearch report dated 25111Oct, 2024, which is available onour website at: https://www.kotaksecurities.com/ksweb/ResearchCall/Fundamenta1. Disclaimer: http://bit.ly/2n5Ax1E https://www.kotaksecurities.oom/ksweb/research/kotak-research-reports/top-weekly-picks
More posts
Share by:
gtag('config', 'AW-634979631');